Business Context and Reporting Period
This Form 8-K reports on the 2010 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on June 2, 2010. The report was filed on June 4, 2010. As of the record date of April 15, 2010, the company had 41,894,605 shares issued and outstanding.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The filing details the outcomes of three specific shareholder votes:
- Director Elections: Stockholders re-elected Victor J. Dzau, M.D., and Kevin P. Starr as Class III directors. The terms of six other directors continued.
- Plan Amendment: Stockholders approved an amendment to the 2004 Employee Stock Purchase Plan.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2010.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is strictly limited to the results of the shareholder vote.
Investor Verification Checklist
- Verify the specific terms of the amendment approved for the 2004 Employee Stock Purchase Plan.
- Confirm the full composition of the Board of Directors following the re-election of Class III directors.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains none.